Purpose: To provide seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated into, a full Yale SPORE in Lung Cancer project. Projects of more limited scope (e.g., for smaller amounts and/or for shorter periods of time) will be at no competitive disadvantage in the review process. Projects with multi-disciplinary collaborations and promising translational research potential will get favorable scores in review. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.
Award Amounts: Up to $50,000 for one year commencing August 1, 2021.
Eligibility: Open to investigators who hold a faculty appointment at an academic institution who can be described by one of the following categories:
a) established investigators in lung cancer who wish to test an innovative, translationally-relevant idea not funded by current or pending grants/funds;
b) junior investigators holding a faculty appointment proposing innovative research in the arena of translational thoracic oncology that require preliminary data to apply for an R01 or equivalent research support;
c) independent investigators with a previous and/or current R01 or equivalent funding whose research to date has not been specifically directed at lung cancer, or even at cancer more generally, but who are interested in exploring the applicability of their particular expertise to lung cancer.
Women and minority investigators are strongly encouraged to apply.
Requirements: If a grant is awarded, the PI and mentors must agree to abide by the Grant Guidelines (page 4) and to participate in the DRP/CEP Symposium to be held at Yale on Thursday, April 14, 2022 (tentative date).
Application Timeline: LOIs are due no later than 11:59 PM on April 23, 2021
Advanced Cardiac Magnetic Resonance Imaging for Detection of Subclinical and Clinical Cardio-Toxicity Associated with Inhibition of the Programmed Cell Death Protein-1 Pathway in the Treatment of Non-Small Cell Lung Cancer (Lauren Baldassarre, MD)
Immune composition and genomic landscape of non-small cell lung cancer from HIV-infected subjects (Brinda Emu, MD)
Profiling functional antibody responses to checkpoint immunotherapy in lung cancer (Aaron Ring, MD, PhD)
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science